Monday, January 31, 2022 Daily Archives

Oxford Biomedica enters US through $180m Homology JV

by

The UK-based gene therapy services firm and Homology Medicines will establish an adeno-associated virus (AAV) manufacturing and innovation joint venture. The deal, expected to close in the next few weeks, will see Oxford Biomedica pay biotech Homology $130 million upfront and invest $50 million in the new entity, ‘Oxford Biomedica Solutions.’ The UK-based gene therapy firm and contract development and manufacturing organization (CDMO) will take an 80% stake in the entity, while Homology will own 20% of the company. The…

January 31, 2022

Lilly pumping $1.45bn into its biomanufacturing network

by

Eli Lilly will invest $1 billion and create nearly 600 jobs at a site in North Carolina. Concurrently, the firm will build a $446 million biologics plant in Ireland. The new facility in Concord, North Carolina will make injectable products and devices, supporting the company’s capacity for its product portfolio and future pipeline. The investment will create nearly 600 jobs and was welcomed by North Carolina state governor Roy Cooper who stated that “Lilly’s choice brings more good jobs to…

January 31, 2022

Biogen pulling out of Bioepis JV in $2.3bn Samsung Bio deal

by

Samsung Biologics will take full ownership Samsung Bioepis 10 years after forming the biosimilar developer with Biogen. In 2012, the relatively new contract development and manufacturing organization (CDMO) Samsung Biologics teamed up with Biogen Idec (now just Biogen) to form a joint venture aimed at developing, manufacturing and marketing biosimilars: Samsung Bioepis. Over the past decade, the share of the entity has shifted – Samsung Biologics began with an 85% share, which later increased to 94.6% before Biogen paid $670…

January 31, 2022

2021 CGT moments: First place for second line CAR-T

by

Advancements in CAR-T development and access, in vivo gene editing, and CDMO M&A all feature in Propel BioSciences’ Susan Nichols top 10 advanced therapy moments of 2021.  After two years away, BioProcess Insider attended the highly anticipated presentation at Phacilitate’s Advanced Therapies Week in Miami, Florida, where Susan Nichols (CEO of Propel BioSciences) highlighted 10 moments from 2021 that defined and drove the cell and gene therapy (CGT) space.  Some unexpected milestones made the list, such as the arrival of messenger…

January 31, 2022